ClinicalTrials.gg
RecruitingNCT07510724IKF-ReWoLuTeUpdated Apr 3, 2026

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

An observational study in Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) and Lung Cancer (Diagnosis), sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Small Cell Lung Carcinoma with a site in Austria — 8 open to participants now, 19 under way, 12 of them phase 3. Small Cell Lung Carcinoma · Austria.

Started
2025
with 3 others
Observational
3 of 39
1 open now
Primary completion
2032-12
later than 18 of 18 live
Registered
38th of 39
by date
Lead sponsor
2 of 39
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 39 studies in Small Cell Lung Carcinoma with a site in Austria, this one is one of 4 that started in 2025, is one of 3 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 38th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

8 of the 39 studies in Small Cell Lung Carcinoma with a site in Austria are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Small Cell Lung Carcinoma with a site in Austria, or all of them as a file.
02

Study summary

The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.

Read the detailed description

The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.

The study includes adult patients with resectable NSCLC (perioperative setting), locally advanced or metastatic NSCLC (1st/2nd line), or extensive-stage SCLC (1st line) who are receiving Tislelizumab according to its approved indications. Approximately 240 patients will be enrolled across about 38 sites.

ReWoLuTe builds on strong clinical evidence from phase III RATIONALE studies and seeks to understand the drug's performance in a broader, more heterogeneous population typically underrepresented in clinical trials. Data collection follows routine clinical practice, including regular assessments during treatment and long-term follow-up for up to five years.

Endpoints include overall survival (primary) and multiple secondary measures such as PFS, DFS, EFS, treatment duration, HRQoL deterioration, and adverse event profiles. Safety data-including immune-mediated events-will be systematically captured and reported according to regulatory requirements.

The study is scheduled to run up to 2033, with interim analyses planned after enrollment and follow-up milestones. Optional archival tissue collection will support accompanying translational research.

03

Conditions studied

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Lung Cancer (Diagnosis)

Keywords

  • Lung Cancer
  • Tislelizumab-based therapy
  • real-world data on tislelizumab treated patients
  • resectable NSCLC (perioperative setting)
  • locally advanced or metastatic NSCLC (1st/2nd line)
  • extensive-stage SCLC (1st line)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The ReWoLuTe study enrolls patients in Germany and Austria of both sexes and ages over 18 years. All patients are diagnosed with resectable non-small cell lung carcinoma (NSCLC) in the perioperative curative setting OR locally advanced or metastatic NSCLC in the 1st or 2nd line therapy setting OR small cell lung carcinoma (SCLC) in the 1st line therapy setting, with no local curative therapy available AND treated with a tislelizumab-based therapy according to label.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has a confirmed resectable Non-small cell lung cancer in stage II-IIIA with high risk of recurrence according to the 8th edition of the following AJCC staging criteria and is eligible for an R0 resection with curative intent and treatment with Tislelizumab in and adjuvant setting:

    1. Tumor size >4cm; or tumors of any size with either N1 or N2 status
    2. Tumors invading thoracic structures (directly into the visceral pleura, parietal pleura, chest wall, main bronchus, phrenic nerve, mediastinal pleura, parietal pericardium)
    3. Tumors >4cm that cause obstructive atelectasis extending to the hilum and involving parts of the lung, the entire lung or a main bronchus, regardless of the distance to the carina, or that invade the visceral pleura (PL1 or PL2)
    4. Tumors with one or more separate nodules in the same lobe as the primary lung carcinoma.

      OR

      Patient has a histologically confirmed locally advanced or lung carcinoma of one of the following subtypes and is eligible for treatment with Tislelizumab in an approved indication:

    5. NSCLC, squamous type, and the patient is not a candidate for surgical resection or platinum-based chemoradiation and did not receive prior treatment in palliative setting,
    6. NSCLC, non-squamous type with expression on ≥50% of tumor cells and without EGFR- or ALK-positive mutations, and patient is not candidate for surgical resection or platinum-based chemoradiation and did not receive prior treatment in palliative setting,
    7. NSCLC, squamous or non-squamous type, and the patient already received prior platinum-based therapy and, if with EGFR- or ALK-positive mutations, also has received targeted therapies,
    8. SCLC, extensive-stage, and the patient has not received prior treatment in palliative setting.
  • A decision for treatment with an authorized Tislelizumab-based regimen has been made by the treating physician before enrolling into ReWoLuTe study.

NOTE:

Patients who have already received 1-2 cycles of therapy are still eligible for enrollment into the NIS. Patients who intended to be treated in the curative setting and had to switch before the start of an adjuvant treatment to the palliative setting or BSC (e.g. due to progress or other reasons), will not be excluded from study.

Exclusion criteria

Exclusion criteria:

  • The patient has not provided signed .
  • The patient is under 18 years of age at the time of providing signed informed consent.
  • The patient is unable to fully comprehend the implications of study participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Lung Cancer patients receiving Tislelizumab according to label

    The study includes adult lung cancer patients with resectable NSCLC (perioperative setting), locally advanced or metastatic NSCLC (1st/2nd line), or extensive-stage SCLC (1st line) who are receiving Tislelizumab according to its approved indications.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Overall survival (OS) is used as measurement to further characterize the effectiveness of tislelizumab therapy in real-world lung cancer patients.

    Time frame: From first Tislelizumab administration up to a maximum of 84 months

Secondary outcomes

  1. Duration of treatment (DoT)

    Duration of treatment (DoT), defined as time from date of first Tislelizumab administration to the date of treatment discontinuation due to any cause.

    Time frame: From enrolment up to a maximum of 84 months.

  2. Progression-free survival (PFS)

    Progression-free survival (PFS), defined as time from date of first Tislelizumab administration to the date of progression according to the attending physician's judgement or death due to any cause, whichever occurs first.

    Time frame: From first Tislelizumab administration up to a maximum of 84 months

  3. Disease-free survival (DFS)

    Disease-free survival (DFS), defined as the time from the date of resection until the first documented disease-related event or death from any cause, whichever occurs first. Disease-related events include local recurrence, regional recurrence, distant metastasis, or the occurrence of a second primary malignancy.

    Time frame: From date of resection up to a maximum of 84 months

  4. Event-Free Survival (EFS)

    Event-Free Survival (EFS) is defined as the time from date of first Tislelizumab administration until the occurrence of any of the following events: disease progression prior to surgery that precludes curative resection, failure to undergo curative-intent surgery for any disease-related reason, postoperative disease recurrence (local, regional, or distant), or death from any cause.

    Time frame: From first Tislelizumab administration up to a maximum of 84 months

  5. Tislelizumab treatment dose in lung cancer patients

    Total treatment dose across lines of therapy in patients treated with Tislelizumab.

    Time frame: From enrolment up to a maximum of 84 months

  6. Tislelizumab treatment frequency in lung cancer patients

    Treatment frequency assessed as numbers of cycles across lines of therapy in patients treated with Tislelizumab.

    Time frame: From enrolment up to a maximum of 84 months

  7. Tislelizumab duration of treatment delays in lung cancer patients

    Duration of of treatment delays across lines of therapy in patients treated with Tislelizumab.

    Time frame: From enrolment up to a maximum of 84 months

  8. Tislelizumab temporary treatment interruptions in lung cancer patients

    Treatment interruptions across lines of therapy in patients treated with Tislelizumab

    Time frame: From enrolment up to a maximum of 84 months

  9. Time to Health-Related Quality of Life (HR-QoL) Deterioration as assessed by EORTC QLQ-C30

    Time to Health-Related Quality of Life (HR-QoL) Deterioration (TTD), measured from start of Tislelizumab treatment to the first ≥10 points decrease of HR-QoL score compared to baseline HR-QoL score with HR-QoL scores derived from EORTC QLQ-C30

    Time frame: From start of Tislelizumab treatment up to a maximum of 84 months

  10. Time to Health-Related Quality of Life (HR-QoL) Deterioration as assessed by EORTC QLQ-LC13

    Time to Health-Related Quality of Life (HR-QoL) Deterioration (TTD), measured from start of Tislelizumab treatment to the first ≥10 points decrease of HR-QoL score compared to baseline HR-QoL score with HR-QoL scores derived from EORTC QLQ-LC13

    Time frame: From start of Tislelizumab treatment up to a maximum of 84 months

  11. Adverse event profiles

    AE frequency, listed with severity, drug-relation, and management of the following groups of AEs: Selected AEs (immune-mediated pneumonitis, colitis, hepatitis, nephritis/renal dysfunction, endocrinopathies, and rash), other immune-mediated AEs (imAEs), other treatment-related AEs, fatal AEs.

    Time frame: From enrolment up to a maximum of 84 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2032, 84 months after the start.

Of 62 observational studies under Small Cell Lung Carcinoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 47. This study's planned 84 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Apr 3, 2026
StartActual
Dec 23, 2025
Primary completionEst.
Dec 23, 2032
CompletionEst.
Jan 23, 2033
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07510724
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
BeOne Medicines
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Dec 23, 2025
Primary completion
Dec 23, 2032 (estimated)
Completion
Jan 23, 2033 (estimated)
Last update
Apr 3, 2026

Study contacts

Akin Atmaca, PD Dr. med.
Contact
atmaca.akin@khnw.de
+49 (0)69 7601 3297
Bianca Zaepf
Contact
rewolute@ikf-khnw.de
+49 (0)69 5899 787-19 ext. or -78
Raoul De Jonge, Dr.
principal investigator · Universitätsklinikum St. Pölten - Lilienfeld, Österreich
Akin Atmaca, PD Dr. med.
principal investigator · Krankenhaus Nordwest, Frankfurt, Deutschland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion